Testing effectiveness (Phase 2)UnknownNCT01600573What this trial is testingPazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)Who this might be right forOvarian Cancer JSehouli 68
Large-scale testing (Phase 3)Study completedNCT00434642What this trial is testingCarboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube CarcinomaWho this might be right forOvarian Cancer Genentech, Inc. 484
Testing effectiveness (Phase 2)Study completedNCT00466986What this trial is testingAbraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian CancerWho this might be right forOvarian CancerFallopian Tube CancerPrimary Peritoneal Cancer Southeastern Gynecologic Oncology 40
Large-scale testing (Phase 3)Ended earlyNCT05329545What this trial is testingUpifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)Who this might be right forHigh Grade Serous Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer Mersana Therapeutics 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT04034927What this trial is testingTesting the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal CancerWho this might be right forFallopian Tube Endometrioid TumorFallopian Tube High Grade Serous AdenocarcinomaMalignant Ovarian Endometrioid Tumor+11 more National Cancer Institute (NCI) 61
Testing effectiveness (Phase 2)Study completedNCT01481701What this trial is testingA Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian CarcinomaWho this might be right forOvarian CarcinomaRelapse Jules Bordet Institute 90
Not applicableStudy completedNCT00368420What this trial is testingValidation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian CancerWho this might be right forOvarian Cancer AGO Study Group 122
Not applicableEnded earlyNCT07000344What this trial is testingApatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP InhibitorWho this might be right forOvarian Cancer Peking Union Medical College Hospital 5
Testing effectiveness (Phase 2)UnknownNCT06161272What this trial is testingFluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPiWho this might be right forOvarian CancerHigh Grade Serous Adenocarcinoma of OvaryPrimary Peritoneal Carcinoma+1 more Guangxi Medical University 80
Early research (Phase 1)Study completedNCT01281514What this trial is testingCarboplatin, PLD and Everolimus in Certain Gynecologic CancerWho this might be right forFallopian Tube CancerPeritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer Fox Chase Cancer Center 21
Testing effectiveness (Phase 2)WithdrawnNCT00369954What this trial is testingGemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or CarboplatinWho this might be right forFallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer Gynecologic Oncology Group
Testing effectiveness (Phase 2)Looking for participantsNCT05231122What this trial is testingPembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian CancerWho this might be right forOvarian Clear Cell AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Endometrial Serous Adenocarcinoma+12 more Roswell Park Cancer Institute 80
Early research (Phase 1)WithdrawnNCT02050009What this trial is testingMetformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerWho this might be right forOvarian Papillary Serous CarcinomaOvarian Serous CystadenocarcinomaRecurrent Fallopian Tube Cancer+3 more Fox Chase Cancer Center
Not applicableStudy completedNCT02222883What this trial is testingPrevalence of BRCA in Patients With Ovarian CancerWho this might be right forBRCA StatusOvarian Cancer AGO Research GmbH 530
Early research (Phase 1)Active Not RecruitingNCT04092270What this trial is testingA Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian CancerWho this might be right forEndometrial High Grade Endometrioid AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+26 more National Cancer Institute (NCI) 55
Testing effectiveness (Phase 2)Study completedNCT00230542What this trial is testingCarboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian CancerWho this might be right forOvarian CancerPeritoneal CancerFallopian Tube Cancer Dana-Farber Cancer Institute 44
Testing effectiveness (Phase 2)UnknownNCT05158062What this trial is testingPembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian CancerWho this might be right forCarcinoma, Ovarian Epithelial Kosei Hasegawa, MD, PhD 35
Large-scale testing (Phase 3)Study completedNCT02855944What this trial is testingARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsWho this might be right forOvarian CancerEpithelial Ovarian CancerFallopian Tube Cancer+1 more pharmaand GmbH 349
Early research (Phase 1)UnknownNCT01387399What this trial is testingSafety and Pharmacokinetics of Intraoperative Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) With Cisplatin to Treat Platinum-sensitive Recurrent Ovarian CancerWho this might be right forOvarian Cancer University Hospital, Bonn 9
Testing effectiveness (Phase 2)Ended earlyNCT00005029What this trial is testingTopotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal CancerWho this might be right forOvarian CancerPrimary Peritoneal Cavity Cancer Gynecologic Oncology Group